This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Vifor Pharma 配当金
配当金 基準チェック /36
主要情報
1.1%
配当利回り
88%
配当性向
| 業界平均利回り | 2.2% |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 一株当たり利益 | US$2.26 |
| 配当利回り予想 | 1.1% |
最近の配当金アップデート
Recent updates
決済の安定と成長
配当データの取得
安定した配当: GNHA.F's dividends per share have been stable in the past 10 years.
増加する配当: GNHA.F's dividend payments have increased over the past 10 years.
配当利回り対市場
| Vifor Pharma 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (GNHA.F) | 1.1% |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.4% |
| 業界平均 (Pharmaceuticals) | 2.2% |
| アナリスト予想 (GNHA.F) (最長3年) | 1.1% |
注目すべき配当: GNHA.F's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.6%).
高配当: GNHA.F's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (4.56%).
株主への利益配当
収益カバレッジ: At its current payout ratio (88.5%), GNHA.F's payments are covered by earnings.
株主配当金
キャッシュフローカバレッジ: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.